CBIO - Catalyst stock surges 95% as GC Biopharma to acquire 3 blood disorder programs

• South Korea's GC Biopharma is acquiring three programs related to orphan blood disorders from Catalyst Biosciences ( NASDAQ: CBIO ).
• The agreement will bring to GC Biopharma programs, including Marzeptacog alfa (MarzAA), an engineered factor VIIa which is ready for phase 3 development, the companies added.
• In its previous trials, "MarzAA" showed efficacy and safety as a therapy for rare bleeding disorders. The treatment is delivered by subcutaneous injection, making it more convenient to administer, according to the companies.
• "We are pleased that GC Biopharma has purchased our hemophilia assets and will continue their clinical development to potentially bring new transformative treatments for several bleeding disorders," said Catalyst President and CEO Nassim Usman.
• In December 2022, Catalyst had completed the first steps in its reverse merger plan .
• CBIO +95.38% to $0.47 premarket Feb. 28

For further details see: